AstraZeneca, Daiichi Sankyo show off ADC portfolio with safety top of mind

A tiny slice of early-stage data for AstraZeneca’s Daiichi Sankyo-partnered antibody drug conjugate showed a high objective response and disease control rate when combined with immune checkpoint inhibitor Imfinzi in patients with non-small cell lung cancer. (NSCLC).